Tudor Investment Corp ET AL lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 78.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,000 shares of the company’s stock after selling 14,158 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Eli Lilly and were worth $336,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC boosted its stake in shares of Eli Lilly and by 79.7% during the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after acquiring an additional 1,719,538 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Eli Lilly and by 93.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Eli Lilly and by 30.3% during the 1st quarter. Alliancebernstein L.P. now owns 3,477,371 shares of the company’s stock worth $292,482,000 after acquiring an additional 808,186 shares in the last quarter. Institutional investors own 75.72% of the company’s stock.
Shares of Eli Lilly and Company (LLY) opened at 83.91 on Friday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The company has a market capitalization of $88.53 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34. The stock has a 50 day moving average price of $80.84 and a 200 day moving average price of $82.02.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the business earned $0.86 earnings per share. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Holdings Cut by Tudor Investment Corp ET AL” was published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/tudor-investment-corp-et-al-has-336000-holdings-in-eli-lilly-and-company-lly/1604683.html.
Several analysts have recently issued reports on the company. BMO Capital Markets reiterated a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Finally, UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 590,000 shares of company stock valued at $48,551,300. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.